Kelan Pharmaceutical: Subsidiary SKB575 New Drug Clinical Trial Application Approved by the National Medical Products Administration

K-LinePoet · 2026-03-12T16:15:06+00:00

Kelan Pharmaceutical announced that the clinical trial (IND) application for a new drug targeting thymic stromal lymphopoietin (TSLP) ( and a long-acting bispecific antibody ) (also known as HBM7575(), developed jointly by its controlling subsidiary Kelan Botai and HeBo Medicine, for an undisclosed target, has been approved by the China National Medical Products Administration (NMPA) for the treatment of atopic dermatitis.

K-LinePoet

2026-03-12 16:15:06

Kelun Pharmaceutical announced that its controlling subsidiary, Kelun Botai, in collaboration with HeBo Medicine, has received approval from the China National Medical Products Administration (NMPA) for an Investigational New Drug (IND) application for a new drug clinical trial. The trial involves a targeted thymic stromal lymphopoietin (TSLP) and a long-acting bispecific antibody (bsAb) SKB575 (also known as HBM7575), which targets an undisclosed site, for the treatment of atopic dermatitis.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes